FMP
2seventy bio, Inc.
TSVT
NASDAQ
2seventy bio, Inc., a cell and gene therapy company, focuses on the research, development, and commercialization of treatments for cancer in the United States. Its products pipeline includes idecabtagene vicleucel; ide-cel or Abecma and bb21217; and CAR-T cell product candidates for the treatment of multiple myeloma. 2seventy bio, Inc. has a collaboration arrangement with Bristol-Myers Squibb Company. The company was incorporated in 2021 and is headquartered in Cambridge, Massachusetts.
4.99 USD
0.01 (0.2%)
TSVT Financial Statements
Year
2024
2023
2022
2021
Total Revenue
37.86M
100.39M
91.5M
54.52M
Cost of Revenue
0
16.92M
26.22M
12.59M
Gross Profit
37.86M
83.47M
65.28M
41.93M
Operating Expenses
153.29M
321.08M
328.19M
355.44M
Research and Development
76.92M
230.76M
248.74M
261.94M
Selling, General & Administrative Expenses
43.92M
69.41M
79.45M
93.51M
Selling & Marketing Expenses
0
0
0
0
General & Administrative Expenses
0
0
0
0
Other Expenses
32.45M
20.91M
6.05M
21.65M
Operating Income
-115.43M
-237.61M
-262.91M
-313.51M
Total Other Income/Expenses Net
58.18M
20.04M
8.76M
21.3M
Income Before Tax
-57.25M
-217.57M
-254.15M
-292.21M
Income Tax
0
0
-8.99k
-16M
Net Income
-57.25M
-217.57M
-254.14M
-276.21M
Basic EPS
-1.1
-4.42
-7.13
-11.71
EPS Diluted
-1.1
-4.42
-7.13
-11.71
Basic Average Shares
52.22M
49.28M
35.64M
23.59M
Diluted Average Shares
52.22M
49.28M
35.64M
23.59M
EBITDA
-98.45M
-206.42M
-251.38M
-297.16M
All figures are in USD.
